ERBB2 and neoplasm: Although ADCs demonstrated promising clinical profiles against HER2-altered tumors, there are still some insurmountable limitations for mAbs such as heterogenous blood perfusion profiles, slow blood clearance which is also associated with tumor uptake, tumor penetration since the molecular weight of antibodies is relatively high (approximately 160 kDa), extravascular binding resulting in increasing turgor effect (interstitial pressure) leading to heterogenous intratumor distribution or stuck at the periphery of the tumor mass.